
News Release

May 25, 2022

Sumitomo Pharma Co., Ltd.

Corrections to “Supplementary Financial Data (IFRS) for the Year Ended March 31, 2022”

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) announced today that the Company has corrected misdescription in a part of the description of the capital expenditures/depreciation and amortization on page 2 and the major consolidated subsidiaries on page 8 of Supplementary Financial Data (IFRS) for the Year Ended March 31, 2022, as follows. The corrected items are indicated with underline.

【Page 2 Capital expenditures】

(Before corrections)

(Billions of yen)

5. Capital Expenditures/ Depreciation and	FY2020	FY2021	Change	FY2022 (Forecast)	Change
Capital expenditures	12.7	<u>12.7</u>	(0.0)	15.9	<u>3.2</u>

(After corrections)

(Billions of yen)

5. Capital Expenditures/ Depreciation and <u>Amortization</u>	FY2020	FY2021	Change	FY2022 (Forecast)	Change
Capital expenditures	12.7	<u>12.6</u>	(0.0)	15.9	<u>3.3</u>

【Page 8 Major Consolidated Subsidiaries】

(Before corrections)

Domestic	Number of employees
Sumitomo Pharma Food & Chemical Co., Ltd.	<u>204</u>
Sumitomo Pharma Animal Health Co., Ltd.	<u>94</u>
Sumitomo Pharma Promo Co., Ltd.	<u>38</u>
Overseas	Number of employees
Sumitomo Pharma America Holdings, Inc.	<u>164</u>
Sunovion Pharmaceuticals Inc.	* <u>1,210</u>
Sumitomo Pharma Oncology, Inc.	<u>190</u>
Sumitovant Biopharma, Inc.	<u>102</u>
Myovant Sciences Ltd.	* <u>565</u>
Urovant Sciences Ltd.	* <u>302</u>

Enzyvant Therapeutics Ltd.	<u>*30</u>
Altavant Sciences Ltd.	<u>*20</u>
Spirovant Sciences <u>Ltd.</u>	<u>*34</u>
Sumitomo Pharma (Suzhou) Co., Ltd.	<u>774</u>

(Reference) Number of employees

	March 31, 2022	
consolidated / non-consolidated	<u>7,023</u>	<u>3,074</u>

(After corrections)

Domestic	Number of employees
Sumitomo Pharma Food & Chemical Co., Ltd.	<u>202</u>
Sumitomo Pharma Animal Health Co., Ltd.	<u>96</u>
Sumitomo Pharma Promo Co., Ltd.	<u>34</u>
Overseas	Number of employees
Sumitomo Pharma America Holdings, Inc.	<u>168</u>
Sunovion Pharmaceuticals Inc.	<u>*1,199</u>
Sumitomo Pharma Oncology, Inc.	<u>191</u>
Sumitovant Biopharma, Inc.	<u>106</u>
Myovant Sciences Ltd.	<u>*569</u>
Urovant Sciences Ltd.	<u>*309</u>
Enzyvant Therapeutics Ltd.	<u>*32</u>
Altavant Sciences Ltd.	<u>*25</u>
Spirovant Sciences, <u>Inc.</u>	<u>*37</u>
Sumitomo Pharma (Suzhou) Co., Ltd.	<u>758</u>

(Reference) Number of employees

	March 31, 2022	
consolidated / non-consolidated	<u>6,987</u>	<u>3,040</u>

Contact:

Corporate Communications

Sumitomo Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)